BIOFLOW-III VIP Russia Registry Orsiro Stent System

Status Recruiting

Clinical Trial Summary

Clinical evaluation of the Orsiro LESS in subjects requiring coronary revascularization with Drug Eluting Stents (DES). Along with it, an explanatory (hypothesis-finding) problem will be investigated, whether the patient's body inflammation status correlates with the clinical outcome.

Clinical Trial Description

For the majority of Coronary Artery Disease (CAD) treatment with Percutaneous Transluminal Coronary Angioplasty (PTCA) provides high initial procedure success. However, the medium to long-term complications range from rather immediate elastic coil or vessel contraction to longer processes like smooth muscle cell proliferation and excessive production of extra cellular matrix, thrombus formation and atherosclerotic changes like restenosis or angiographic re-narrowing. The reported incidence of restenosis after PTCA ranges from 30 to 50%. Such rates of recurrence have serious economic consequences. Bare Metal Stents (BMS), designed to address the limitations of PTCA, reduced the angiographic and clinical restenosis rates in De Novo lesions compared to PTCA alone and decreased the need for CABG. BMS substantially reduced the incidence of abrupt artery closure, but restenosis still occurred in about 20 to 40% of cases, necessitating repeat procedures.

The invention of Drug Eluting Stents (DES) significantly improved on the principle of BMS by adding an antiproliferative drug (directly immobilized on the stent surface or released from a polymer matrix), which inhibits neointimal hyperplasia. The introduction of DES greatly reduced the incidence of restenosis and resulted in better safety profile as compared to BMS with systemic drug administration. These advantages and a lower cost compared to surgical interventions has made DES an attractive option to treat coronary artery disease.

Therefore this observational registry has been designed for the clinical evaluation of the ORSIRO LESS requiring coronary revascularization with DES. It is designed to investigate and collect clinical evidence for the clinical performance and safety of the Orsiro Drug Eluting Stent System in an all-comers patient population in daily clinical practice.

Along with it, an explanatory (hypothesis-finding) problem will be investigated, whether the patient's body inflammation status correlates with the clinical outcome. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT02247492
Study type	Observational [Patient Registry]
Source	Biotronik Russia
Contact	Ildar Khassanov, Dr.
Phone	+49 9131 852 56 34
Email	ildar.khassanov@biotronik.com
Status	Recruiting
Phase
Start date	April 14, 2017
Completion date	May 2021

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT00328315` - Cardiac SPECT With Rotating Slant Hole Collimator
Recruiting	`NCT02257710` - BIOFLOW-III UK Satellite Registry Orsiro Stent System	N/A
Active, not recruiting	`NCT02273648` - BIOTRONIK - BIOFLOW-III Registry French Satellite	N/A
Recruiting	`NCT01157455` - A Registry To Evaluate Safety And Effectiveness Of Everolimus Drug Eluting Stent For Coronary Revascularization	Phase 4
Completed	`NCT02028728` - BIOFLOW III Satellite-Italy Orsiro Stent System	N/A
Completed	`NCT02813473` - SYNTAX III REVOLUTION Trial: A Randomized Study Investigating the Use of CT Scan and Angiography of the Heart to Help the Doctors Decide Which Method is the Best to Improve Blood Supply to the Heart in Patients With Complex Coronary Artery Disease
Completed	`NCT05853250` - Clinical and Hospital Stay Effects of Reiki and Manual Therapy After Open Heart Surgery	N/A
Recruiting	`NCT02635230` - What is the Optimal antiplatElet and Anticoagulant Therapy in Patients With Oral Anticoagulation Undergoing revasculariSaTion 2.
Completed	`NCT01116882` - Percutaneous Coronary Intervention (PCI) Outcomes in Community Versus Tertiary Settings	N/A
Completed	`NCT00920283` - COMPETE: A Clinical Evaluation of Chrono Carbostent Carbofilm™ Coated Stent	N/A
Completed	`NCT01700075` - Physical and Chemical Study of Atherosclerosis Mechanisms	Phase 4
Completed	`NCT00607178` - The Efficacy of Influenza Vaccine in Reducing Cardiovascular Events in Patients With Coronary Artery Diseases	Phase 2/Phase 3
Completed	`NCT00607217` - The Efficacy of Influenza Vaccination in Patients With Coronary Artery Diseases	Phase 2/Phase 3
Not yet recruiting	`NCT05486780` - The Effect of Digital Window on Day and Night Perception Status and Sleep Quality in Intensive Care Patients	N/A
Terminated	`NCT01665248` - Comparison of 18-F Sodium Fluoride Uptake in Culprit Plaques Between Acute Coronary Syndrome and Stable Angina	N/A
Terminated	`NCT01612819` - DXR Stent(Previous Cilotax) Implantation Registry	N/A
Active, not recruiting	`NCT01226355` - NOYA CoCr Biodegradable Coating Sirolimus-Eluting Coronary Stent System	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.